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Association between contemporary hormonal contraception  
and ovarian cancer in women of reproductive age in Denmark: 
prospective, nationwide cohort study
Lisa Iversen,1 Shona Fielding,2 Øjvind Lidegaard,3 Lina S Mørch,3 Charlotte W Skovlund,3 
 Philip C Hannaford1
AbstrAct
Objectives
To investigate the association between contemporary 
combined hormonal contraceptives (including 
progestogen types in combined preparations and all 
progestogen-only products) and overall and specific 
types of ovarian cancer.
Design
Prospective, nationwide cohort study.
setting
Denmark, 1995-2014.
ParticiPants
All women aged 15-49 years during 1995-2014 were 
eligible. Women were excluded if they immigrated 
after 1995, had cancer (except non-melanoma skin 
cancer), had venous thrombosis, or were treated for 
infertility before entry (final study population included 
1 879 227 women). Women were categorised as 
never users (no record of being dispensed hormonal 
contraception), current or recent users (≤1 year after 
stopping use), or former users (>1 year after stopping 
use) of different hormonal contraceptives.
Main OutcOMe Measures
Poisson regression was used to calculate relative risk 
of ovarian cancer among users of any contemporary 
combined hormonal contraceptives and by 
progestogen type in combined preparations and 
all progestogen-only products, including non-oral 
preparations. Separate analyses examined women 
followed up to their first contraception type switch 
and those with full contraceptive histories. Duration, 
time since last use, and tumour histology were 
examined and the population prevented fraction were 
calculated.
results
During 21.4 million person years, 1249 incident 
ovarian cancers occurred. Among ever users of 
hormonal contraception, 478 ovarian cancers were 
recorded over 13 344 531 person years. Never users 
had 771 ovarian cancers during 8 150 250 person 
years. Compared with never users, reduced risks 
of ovarian cancer occurred with current or recent 
use and former use of any hormonal contraception 
(relative risk 0.58 (95% confidence interval 0.49 to 
0.68) and 0.77 (0.66 to 0.91), respectively). Relative 
risks among current or recent users decreased 
with increasing duration (from 0.82 (0.59 to 1.12) 
with ≤1 year use to 0.26 (0.16 to 0.43) with >10 
years’ use; P<0.001 for trend). Similar results were 
achieved among women followed up to their first 
switch in contraceptive type. Little evidence of 
major differences in risk estimates by tumour type or 
progestogen content of combined oral contraceptives 
was seen. Use of progestogen-only products were 
not associated with ovarian cancer risk. Among ever 
users of hormonal contraception, the reduction in the 
age standardised absolute rate of ovarian cancer was 
3.2 per 100 000 person years. Based on the relative 
risk for the never use versus ever use categories 
of hormonal contraception (0.66), the population 
prevented fraction was estimated to be 21%—that 
is, use of hormonal contraception prevented 21% of 
ovarian cancers in the study population.
cOnclusiOns
Use of contemporary combined hormonal 
contraceptives is associated with a reduction in 
ovarian cancer risk in women of reproductive age—an 
effect related to duration of use, which diminishes 
after stopping use. These data suggest no protective 
effect from progestogen-only products.
Introduction
Hormonal contraception is popular. At least 100 
million women worldwide use hormonal contraception 
every day.1 In 2012, an estimated 238 719 women 
around the world were diagnosed with a new ovarian 
cancer and 151 917 died from the condition.2 Survival 
from ovarian cancer is poorer than from many other 
cancers; with an overall, age standardised survival 
rate at five years of 30-40% worldwide, varying 
according to stage at diagnosis.3 Previous research 
has shown a reduced risk of ovarian cancer in users of 
combined oral contraceptives, an effect that persists 
for many years after stopping use.4-9 However, most 
of the evidence relates to the use of older and higher 
WhAt Is AlreAdy knoWn About thIs topIc
Previous research relating to the use of older and higher dose preparations of 
oestrogen containing older progestogens has shown a reduced risk of ovarian 
cancer in users of combined oral hormonal contraceptives
This reduced risk has been shown to persist for many years after stopping use of 
these combined oral contraceptives
WhAt thIs study Adds
In this large, prospective, population based study of women aged 15-49 years in 
Denmark, use of contemporary combined oral contraceptives containing newer 
progestogens was associated with a reduction in the risk of ovarian cancer
Few women in the study were exclusive users of progestogen-only contraceptives; 
therefore, evidence regarding progestogen-only contraceptives was limited, with 
no evidence of beneficial ovarian cancer effects among exclusive users of these 
products
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dose preparations of oestrogen containing older 
progestogens. Therefore, this evidence might not 
reflect the impact of substantial changes in hormonal 
contraception that have occurred over time. Such 
changes have occurred in formulations of combined 
oral contraceptives (notably reductions in oestrogen 
dose and the introduction of newer progestogens such 
as desogestrel, gestodene, and drospirenone), patterns 
of administration (continuous v monthly cycles in 
which 21 days of combined hormonal contraception 
is followed by seven hormone-free days during which 
a withdrawal bleed occurs), new non-oral routes of 
administration, and an increased use of progestogen-
only preparations.10
It is important for users of contemporary combined 
oral contraceptives to know whether they are likely 
to experience the same pattern of ovarian cancer 
benefit as users in the older studies, and whether 
a benefit is specific to any particular formulation. 
Users of other hormonal contraceptive methods 
(including progestogen-only oral contraceptives and 
the levonorgestrel releasing intrauterine system) 
also should know whether they are at a reduced risk 
of ovarian cancer. Such information is important for 
putting into context the risks of other known cancers 
linked to contemporary hormonal contraception, such 
as breast cancer.11 Current evidence is insufficient for 
combined oral contraception4-9 as well as for other 
types of hormonal contraception.12-16 We report here 
a large investigation of contemporary hormonal 
contraceptive use and ovarian cancer in a national 
cohort of young Danish women.
Methods
Data linkage
The Danish Sex Hormone Register Study, which has 
been described previously,17 18 follows a national 
cohort of women aged 15-79 years. It was established 
to investigate the relation between hormone use and 
the risk of cancer or cardiovascular disease. The study 
dataset uses an individual’s personal identification 
number in the Civil Registration System to link data 
from several national registries: 
•	 Statistics Denmark, for education information
•	  National Register of Medicinal Product Statistics, 
for hormonal contraceptive prescriptions dispensed 
since January 1994 and considered complete since 
1 January 1995
•	  Danish Cancer Registry, for histologically 
verified cancers since 1943 and family history of 
premenopausal (age <50 years) breast or ovarian 
cancer in mothers or sisters
•	  National Birth Register, for all births since 1973 and 
information on smoking status (since 1991) and 
body mass index (since 2004)
•	  National Health Register, for hospital discharge 
diagnoses and surgeries since 1977. 
The personal identification number system, in use 
since 1968, assigns a unique number to each resident 
in Denmark and is used as a key personal identifier 
in all national registries, thereby ensuring accurate 
linkage of different databases.
study population
All women living in Denmark aged 15-49 years from 
1 January 1995 to 31 December 2014 were eligible 
for the study unless they immigrated after 1995 (total 
number eligible=1 904 094). Women were excluded 
if they had cancer (except non-melanoma skin 
cancer), had venous thrombosis, or were treated for 
infertility before study entry (indicated by a redeemed 
prescription for ovarian stimulating drugs, Anatomical 
Therapeutic Chemical Classification (ATC) system code 
MG03G in the National Prescription Registry). The final 
study population comprised 1 879 227 women. The 
women were followed up to first diagnosis of ovarian 
cancer (ICD-10 (international classification of diseases, 
10th revision)19 code C56), death, emigration, age 
50 years, or end of follow-up (31 December 2014), 
whichever came first. During follow-up, women were 
censored permanently at the date of diagnosis of non-
ovarian cancer (except non-melanoma skin cancer), 
infertility treatment, venous thrombosis, bilateral 
oophorectomy, or second unilateral oophorectomy. 
Women were censored temporarily during pregnancy 
and for six months after delivery.
Hormonal contraception
Information about redeemed prescriptions included 
date of redemption, ATC code, dose, number 
of packages, defined daily doses, and route of 
administration. These data were updated daily to 
allow identification of when women started use 
(date when prescription was redeemed), stopped use 
(estimated date when prescription finished, based on 
number of packs issued), or switched use of hormonal 
contraception (redemption date of prescription for a 
different product). Using the methods of Nielsen and 
colleagues,20 gaps between prescriptions of fewer than 
28 days were filled in prospectively. We assumed that 
the levonorgestrel intrauterine system was used for four 
years unless another hormonal contraceptive product 
was redeemed or pregnancy occurred before the end 
of the four year period. Women were categorised as 
never users (no record of being dispensed hormonal 
contraception), current or recent users (up to one 
year after stopping use), or former users (more than 
one year after stopping use) of different hormonal 
contraceptives.
statistical analysis
We calculated age standardised incidence rates of 
ovarian cancers per 100 000 person years, using the 
age distribution of the cohort as standard. Risk of 
ovarian cancer among users of the different product 
groups was analysed by a Poisson regression model 
in SAS version 9.3 (SAS Institute). Adjusted incidence 
rate ratios (referred to here as relative risks) and their 
surrounding 95% confidence intervals were calculated 
for each model, with never users as the reference 
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group. The adjusted models included the following 
time varying covariates: 
•	 Calendar year
•	 Hormonal contraceptive use
•	 Parity (0, 1, 2, 3, 4, >4)
•	  Age group (15-19, 20-24, 25-29, 30-34, 35-39, 40-
44, 45-49 years)
•	  Education (elementary school only, high school 
only, further education excluding college/university, 
college/university education, university education 
with research qualifications, unknown)
•	 Tubal sterilisation (yes, no)
•	 Hysterectomy (yes, no)
•	 Endometriosis (yes, no)
•	 Polycystic ovary syndrome (yes, no)
•	 Family history of breast or ovarian cancer (yes, no). 
Additional models adjusting for smoking status 
(current smoker, non-smoker, unknown at the time 
smoking status was ascertained antenatally) and body 
mass index when ascertained antenatally (<18.5, 
18.5-25, >25-30, >30, unknown), were carried out in 
the subset of parous women with this information.
The main analysis compared ever users, former 
users, and current or recent users of any hormonal 
contraception with never users as reference. Separate 
analyses stratified the data by duration of use, by time 
since last current use, and by ovarian tumour histology. 
Ovarian tumour histology used the same groupings 
as the Collaborative Group on Epidemiological 
Studies of Ovarian Cancer,4 and used the following 
ICD-O-3 codes21: epithelial clear cell (M8310/8313), 
epithelial endometrioid (M8380), epithelial 
mucinous (M8470/8480/8490), and epithelial serous 
(M8441/8460); non-epithelial (M8620/8631/8650/8
862/8890/8933/8951/8963/9080/9084/9110); and 
malignant tumour not otherwise specified (all other 
morphology codes supplied alongside the C56 cancer 
registration) and ending with the behaviour invasive 
digit 3. We tested for the trends for duration of use and 
time since last current use by including the duration/
time since variables as an ordinal variable, with values 
set to the median duration within each category.22
Comparisons between main contraceptive groupings 
were also conducted for women followed up to their 
first change in hormonal contraception, for those aged 
15 years on or after 1 January 1995 (that is, those with 
a fully documented hormonal contraceptive history), 
and for epithelial ovarian cancers only. Previous 
studies have indicated a persisting protective effect 
from previous use of oral combined contraception.4 
6 9 To minimise the effects of previous use while 
ensuring that we had sufficient data for analysis, our 
risk estimates for different hormonal preparations 
were derived mainly among women followed up to 
their first change in hormonal contraception during 
the study. Up to 31 December 2003, tumour staging 
in the Danish Cancer Registry used the International 
Federation of Gynaecology and Obstetrics (FIGO) 
staging classification,23 after which the Union for 
International Cancer Control Tumour, Node, Metastasis 
(TNM) classification was used.24 When necessary, we 
converted TNM classification information into the FIGO 
stage classification.25 We then examined tumour FIGO 
stage by age at diagnosis and calculated the frequency 
of the different tumour types by stage at diagnosis. 
We calculated the population prevented fraction 
(population prevented fraction=prevalenceexposure(1−
relative risk)) associated with ever use of any hormonal 
contraception by using the relative risk of never 
use versus ever use of any hormonal contraception. 
The population prevented fraction is the proportion 
(expressed as a percentage) of the ovarian cancers in 
the cohort that has been prevented by ever use of any 
hormonal contraception.
Patient and public involvement
Patients or members of the public were not invited to 
comment on the research question, study design, or 
to interpret the results. Since this was a population 
study using existing data, asking them to share patient 
relevant outcomes was not possible. They were not 
invited to contribute to the writing or editing of this 
document for readability or accuracy. The results 
will be shared with the media and disseminated to 
members of the public through appropriate media 
channels.
results
During the 20 year study period, 1249 women aged 
15-49 years had incident ovarian cancer during more 
than 21.4 million person years of observation (about 
11.4 years per woman). At study entry, 756 943 women 
younger than 20 years then had a mean follow-up of 
10.8 years (standard deviation 6.0), 379 808 aged 
20-29 years had a mean follow-up of 16.8 (5.0) years, 
373 167 aged 30-39 years had a mean follow-up 
of 13.8 (4.2) years, and 369 309 aged 40 years and 
older had a mean follow-up of 4.7 (2.9) years. During 
13 344 531 person years of follow-up, 478 ovarian 
cancers were found among ever users of any hormonal 
contraception. In never users, 771 ovarian cancers 
occurred during 8 150 250 person years. Median age at 
ovarian cancer diagnosis was 44.4 years (interquartile 
range 38.9-47.7). Most hormonal contraceptive use 
was related to combined oral contraception (86%, 
7 612 267/8 839 374 person years of current or 
recent use; table 1). Current or recent users of the 
levonorgestrel intrauterine system were older and more 
likely to be parous than women using other products. 
Generally, a higher percentage of parous women were 
using non-oral routes of hormonal contraception 
or oral progestogen-only products than nulliparous 
women. Few women (contributing about 2-3% of total 
person years) had a family history of early (before age 
50 years) ovarian or breast cancer.
The age adjusted incidence of ovarian cancer was 
highest in women who were never users of hormonal 
contraception (7.5 per 100 000 person years; table 2). 
Among ever users of hormonal contraception, reduction 
in the age standardised absolute rate of ovarian cancer 
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was 3.2 per 100 000 person years. Overall, ever users 
of any hormonal contraception had a reduced risk of 
ovarian cancer compared with never users (relative risk 
0.66 (95% confidence interval 0.58 to 0.76)). Reduced 
risk estimates were also observed for current or recent 
use of any hormonal contraception (0.58 (0.49 to 
0.68)) as well as for former use (0.77 (0.66 to 0.91)). 
Current or recent users of progestogen-only products 
seemed to have a smaller reduction in ovarian cancer 
risk than users of combined oral contraceptives. The 
reduced risk of ovarian cancer among current users 
was stronger with increasing duration of hormonal 
contraceptive use. The reduced ovarian cancer 
risk among previous hormonal contraceptive users 
diminished with time since stopping use, and was non-
significant by 10 years after last use. When both time 
since last use and duration were examined, evidence 
among former users of any hormonal contraception 
indicated greater protection with longer durations of 
use and a suggestion that the protection waned more 
quickly in those with shorter durations of use (table 3).
Among women followed in the cohort up to their 
first switch in hormonal contraception (71% of the 
total period of observation, 15 333 680 person years), 
there was little evidence of important differences 
between combined oral contraceptives containing 
different progestogens, at least for those with sufficient 
usage to produce precise risk estimates (table 4). In 
this analysis, progestogen-only products, including 
the levonorgestrel containing intrauterine system, 
did not protect against ovarian cancer. For combined 
products, the pattern of relative risks seen in the full 
cohort (that is, women followed beyond their first 
switch in hormonal contraception) were similar (table 
1S). Overall similar risk estimates were found in both 
the full cohort and among parous women followed up 
to their first switch in hormonal contraception when 
we adjusted for smoking and body mass index (data 
not shown).
Restricting the analysis to women with a complete 
contraception exposure history (those aged 15 years on 
or after 1 January 1995) reduced the cohort to 596 395 
women (31.7% of total number) contributing 25% 
of the total period of observation (5 417 268 person 
years) and 6% of all ovarian cancers, reflecting the 
younger age of this subset of women. Most of the risk 
table 1 | characteristics of never, former, and current or recent users of different types of hormonal contraception
type of hormonal 
contraception (dates  
on market during study*)
no of 
person  
years 
age (years; 
mean (sD))
education 
(%)† nulliparous 
(%)
PcOs 
(%)
tubal 
 sterilisation 
(%)
Hysterectomy 
(%)
endometriosis 
(%)
Family 
history 
(%)‡
bMi 
(mean 
(sD))§
smoking 
(%)¶e u
Main use groups
Never use 8 150 250 35.4 (11.8) 22.5 5.4 86.3 0.1 6.9 2.6 0.4 2.3 24.6 (5.3) 21.5
Former use, >12 months ago 4 505 157 36.8 (8.0) 18.0 9.4 46.7 0.3 9.9 2.2 1.0 2.8 24.2 (5.0) 24.5
Current or recent use 8 839 374 29.2 (8.3) 14.3 7.1 74.8 0.2 1.1 0.2 0.4 2.5 24.4 (5.0) 24.7
current or recent use of combined hormonal contraception
Oral, 50 µg ethinylestradiol 
 Norethisterone (1995-2002) 57 516 32.3 (8.7) 32.6 2.0 89.4 0.03 2.7 0.3 0.2 2.5 24.8 (5.5) 46.6
 Levonorgestrel (1995-2009) 82 756 34.6 (9.5) 31.4 3.5 86.5 0.06 3.3 0.4 0.5 2.5 24.9 (5.4) 45.9
Oral, 20-40 µg ethinylestradiol 
 Norethisterone (1995-) 165 211 28.2 (7.7) 21.9 4.0 86.6 0.04 1.0 0.1 0.1 2.8 25.1 (5.3) 31.9
 Levonorgestrel (1995-) 1 016 015 30.5 (8.8) 15.7 6.0 77.1 0.2 0.9 0.1 0.3 2.3 24.5 (5.0) 27.6
 Norgestimate (1995-) 721 004 27.9 (7.8) 14.8 6.5 78.3 0.2 0.9 0.1 0.3 2.4 24.6 (5.1) 27.8
 Desogestrel (1995-) 1 659 258 27.6 (7.9) 13.6 6.8 79.8 0.1 0.7 0.1 0.4 2.4 24.5 (5.0) 26.2
 Gestodene (1995-) 2 985 909 27.7 (7.8) 14.2 6.3 79.7 0.1 0.7 0.1 0.3 2.4 24.7 (5.1) 26.5
 Drospirenone (2001-) 592 556 26.6 (7.8) 9.8 8.8 78.4 0.5 0.7 0.1 0.5 2.3 24.1 (4.8) 24.2
 Cyproterone (1995-) 317 961 27.3 (7.2) 11.8 8.6 85.3 1.1 0.7 0.1 0.3 2.3 23.7 (4.8) 28.0
 Estradiol valerate, dienogest  
 (2009-)
14 081 33.9 (10.1) 8.8 11.6 55.3 1.0 2.5 0.6 1.4 2.2 23.7 (4.6) 19.2
Non-oral
 Patch (2003-) 15 358 27.0 (7.7) 18.6 4.4 63.6 0.5 1.0 0.1 0.6 1.7 23.8 (4.9) 28.3
 Vaginal ring (2002-) 124 280 28.2 (7.0) 9.8 12.5 68.6 0.4 0.5 0.0 0.5 2.2 24.0 (4.7) 24.0
current or recent use of progestogen-only products
Oral 
 Norethisterone (1995-) 158 073 34.8 (8.3) 17.4 9.2 57.7 0.1 1.1 0.2 0.4 2.8 23.9 (4.7) 20.0
 Levonorgestrel (1995-2005) 11 544 37.6 (8.3) 22.1 7.9 80.1 0.0 1.1 0.3 0.1 2.9 24.2 (4.5) 18.3
 Desogestrel (2001-) 123 539 32.4 (8.3) 10.8 12.7 45.1 0.1 1.2 0.1 0.4 2.9 24.0 (4.8) 18.5
Non-oral
 MPA depot (1995-) 27 832 27.7 (8.9) 43.7 0.5 72.5 0.3 2.3 0.2 0.5 2.4 26.0 (6.4) 54.5
 Implant (1999-) 58 371 26.9 (8.4) 24.2 2.7 68.4 0.3 1.6 0.2 0.3 2.1 25.3 (5.8) 35.4
 LNG-IUS (1995-) 708 111 40.0 (6.6) 11.6 11.2 33.5 0.2 4.2 1.4 1.1 2.9 24.1 (4.7) 18.7
Descriptive statistics calculated as the average person time with a given characteristic divided by the total amount of person time on a specific hormonal contraceptive; descrip-
tive percentages represent the percentage of person time with a given characteristic. 
BMI=body mass index; E=elementary school; LNG-IUS=levonorgestrel intrauterine system; MPA=medroxyprogesterone acetate; PCOS; polycystic ovary syndrome; SD=standard 
deviation; U=university.
*From this year onwards to end of the study. 
†Percentage of participants with elementary school education only and percentage with university education. 
‡Family history of premenopausal breast or ovarian cancer. 
§Available since 2004 only in parous women (n=322 641, 73% unknown body mass index). 
¶Available since 1991 only in parous women (n=512 143, 57% unknown smoking).
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estimates were imprecise although broadly compatible 
with the results of the main analyses (table 2S).
Current or recent use of any hormonal contraception 
was associated with a reduced risk of any epithelial 
ovarian cancer, in particular endometrioid, mucinous, 
and serous epithelial cancer (table 5). There was not 
a significant reduction in clear cell epithelial or non-
epithelial ovarian cancer. When the subset of epithelial 
ovarian cancers (773/1064, 73% of the total ovarian 
cancers) was examined among women followed up 
to their first switch in hormonal contraception (table 
3S), the pattern of relative risks for different hormonal 
contraceptives was similar to that seen for all ovarian 
cancers.
Age at diagnosis was associated with FIGO stage 
with a higher percentage of women in the oldest age 
group being diagnosed at stage III or IV in comparison 
with younger women (table 4S; Ptrend<0.001). Over 60% 
(323/502) of serous tumours were diagnosed at stage 
III or IV compared with 15% (30/204) of mucinous 
tumours (table 5S). Based on the relative risk for the 
never use versus ever use categories of hormonal 
contraception (0.66), the population prevented 
fraction was estimated to be 21%—that is, use of 
hormonal contraception prevented 21% of ovarian 
cancers in the study population.
discussion
Principal findings
In this study of women of reproductive age (that 
is, younger than 50 years) living in Denmark, we 
found that ever use of any contemporary hormonal 
contraception was associated with a reduced risk of 
ovarian cancer, an effect that strengthened with longer 
periods of current use and persisted for several years 
after stopping use. Most of the hormonal contraceptive 
use related to combined oral contraceptives. There 
was little evidence of important differences between 
combined oral contraceptives containing different 
types of progestogens. The reduced risk associated with 
hormonal contraception was seen with nearly all types 
of ovarian cancer. Our data do not suggest a protective 
effect from progestogen-only products; however, few 
women were exclusive users of such products, and 
so we had limited statistical power to detect such an 
effect.
strengths and limitations of study
Strengths of our study included its nationwide 
coverage of nearly 1.9 million women, more than 21 
million person years of prospective follow-up, and the 
examination of the many different forms of hormonal 
contraception currently available. The linkage of 
prescribing and cancer registration information 
avoided recall bias regarding patterns of hormonal 
contraception use. Similar to most studies of hormonal 
contraceptives, we have assumed that women who were 
dispensed a prescription subsequently used it. If some 
women did not (that is, they remained being a non-user 
when we incorrectly deemed them to be a user), such 
misclassification would underestimate the protective 
effects found. However, because of the time varying 
variables used in our study, this misclassification of 
current use would only be present for the time period 
of the redeemed prescription. Thereafter, the women 
would be classified as a non-taker.
The data linkage study design also enabled us to 
adjust for several important confounding variables. 
The cohort was younger than 50 years, and so few 
women will have used hormone replacement therapy 
known to increase ovarian cancer risk.26 While this age 
restriction meant that we could be confident that we 
were examining the effects of oral contraception, it also 
meant that the study could not provide information on 
how contemporary hormonal contraceptives affected 
ovarian cancer risk in older women, in whom most 
cases of ovarian cancer occur. We were not able to 
adjust for some factors, such as breastfeeding, and 
table 2 | relative risk of ovarian cancer in users of hormonal contraception according to time since last current use and 
duration of current use
use category no of person years
no of ovarian 
cancer events
age standardised incidence 
per 100 000 person years
adjusted relative risk 
(95% ci)*
Never use 8 150 250 771 7.5 1.00
Ever use (any hormonal contraception) 13 344 531 478 4.3 0.66 (0.58 to 0.76)
Former use (any hormonal) 4 505 157 244 5.0 0.77 (0.66 to 0.91)
Current or recent use (any hormonal) 8 839 374 234 4.0 0.58 (0.49 to 0.68)
Current or recent use (combined oral) 7 751 904 175 3.8 0.53 (0.45 to 0.64)
Current or recent use (progestogen only) 1 087 470 59 4.2 0.72 (0.55 to 0.95)
Duration of current or recent use of any hormonal contraception† 
 ≤1 year 1 265 020 42 5.9 0.82 (0.59 to 1.12)
 >1-≤5 years 4 063 111 103 4.6 0.62 (0.50 to 0.77)
 >5-≤10 years 2 580 300 71 4.4 0.57 (0.44 to 0.74)
 >10 years 930 943 18 1.7 0.26 (0.16 to 0.43)
Time since last current use of any hormonal contraception‡
 >1-≤5 years 2 442 620 110 5.0 0.76 (0.61 to 0.93)
 >5-≤10 years 1 397 257 83 4.3 0.78 (0.61 to 0.99)
 >10 years 665 281 51 3.8 0.80 (0.59 to 1.08)
*Adjusted for calendar year, parity, age, education, tubal sterilisation, hysterectomy, endometriosis, polycystic ovary syndrome, and family history of breast 
or ovarian cancer.
†Ptrend<0.001.
‡Ptrend=0.03.
 o
n
 12 June 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.k3609 on 26 September 2018. Downloaded from 
RESEARCH
6 doi: 10.1136/bmj.k3609 | BMJ 2018;362:k3609 | the bmj
information about endometriosis and polycystic ovary 
syndrome only related to women admitted to hospital 
for these conditions. Our findings, therefore, could 
be subject to residual confounding. Information on 
smoking and body mass index was only available in 
parous women for part of the study period. However, 
adjustment for these variables in the subset of women 
for whom these data were available did not materially 
change the risk estimates.
The low incidence of ovarian cancer among women 
followed up to their first switch in type of hormonal 
contraception meant that it was not possible to 
examine the association between duration of use and 
time since last current use among users of specific 
preparations. However, given the little evidence overall 
of major differences between preparations, it seems 
unlikely that there are important differences in these 
temporal associations.
We did not have information about hormonal 
contraceptives prescribed before entry to the study. 
Some women who were classified as never users could 
have used hormonal contraception previously. Such 
misclassification would underestimate the protective 
risk estimates, a problem that should diminish the 
further a woman was from her last use. Because older 
women are further away from their last use, and 
because most instances of ovarian cancer occur in 
older women (71% of our events were in women older 
than 40 years), we do not believe that our results were 
seriously affected by this misclassification. Some of 
the effects attributed to the use of a particular product 
could reflect lingering effects from the use of a previous 
product or products. Our analysis of women followed 
to their first switch of hormonal contraception in the 
study was intended to minimise such effects, while still 
providing enough data for reliable risk estimates. Little 
table 3 | relative risk of ovarian cancer in former users of hormonal contraception by time since last current use and duration of use
Duration of use
time since last current use of hormonal contraception
1-<5 years 5-<10 years ≥10 years
no of person 
years
no of ovarian 
cancer events
relative risk 
(95% ci)*
no of person 
years
no of ovarian 
cancer events
relative risk 
(95% ci)*
no of person 
years
no of ovarian 
cancer events
relative risk 
(95% ci)*
≤1 year 667 835 37 0.81  
(0.58 to 1.13)
470 243 45 1.14  
(0.84 to 1.56)
316 850 27 0.81  
(0.54 to 1.21)
>1-≤5 years 1 038 886 47 0.84  
(0.62 to 1.15)
635 891 29 0.66  
(0.45 to 0.98)
308 126 22 0.76  
(0.48 to 1.20)
>5 years 735 899 26 0.60  
(0.39 to 0.91)
291 123 9 0.41  
(0.21 to 0.81)
40 304 2 0.57  
(0.14 to 2.33)
*Adjusted for calendar year, parity, age, education, tubal sterilisation, hysterectomy, endometriosis, polycystic ovary syndrome, and family history of breast or ovarian cancer.
table 4 | relative risk of ovarian cancer in users by different types of hormonal contraception in women followed up to 
their first switch in hormonal contraception (that is, the no change cohort)
no of person years no of cancer events adjusted relative risk (95% ci)*
Never use 8 150 250 771 1.00
Ever use (any hormonal contraception) 7 183 430 293 0.73 (0.63 to 0.84)
Former use (any hormonal) 2 590 322 164 0.85 (0.71 to 1.02)
Current or recent use (any hormonal) 4 593 109 129 0.61 (0.50 to 0.74)
Current or recent use (combined OC) 4 316 888 103 0.56 (0.45 to 0.70)
Current or recent use (progestogen only) 276 221 26 0.87 (0.59 to 1.29)
Current or recent use of combined hormonal contraception—oral
 Norethisterone, 50 µg ethinylestradiol 36 494 4 1.35 (0.50 to 3.61)
 Levonorgestrel, 50 µg ethinylestradiol 47 335 6 1.21 (0.54 to 2.71)
 Norethisterone, 30-35 µg ethinylestradiol 116 090 7 1.30 (0.62 to 2.76)
 Levonorgestrel, 30-35 µg ethinylestradiol 519 113 11 0.33 (0.18 to 0.61)
 Desogestrel, 20-30 µg ethinylestradiol 988 952 17 0.45 (0.27 to 0.73)
 Gestodene, 20-35 µg ethinylestradiol 1 887 047 42 0.57 (0.41 to 0.79)
 Drospirenone, 20-35 µg ethinylestradiol 188 928 5 1.08 (0.44 to 2.64)
 Norgestimate, 35 µg ethinylestradiol 375 778 11 0.75 (0.41 to 1.37)
 Cyproterone, 30 µg ethinylestradiol 142 147 0 —
 Estradiol valerate, dienogest 1022 0 —
Current or recent use of combined hormonal contraception—non-oral 
 Patch 2253 0 —
 Vaginal ring 11 729 0 —
Current or recent use of progestogen-only contraception—oral
 Norethisterone 66 934 4 0.62 (0.23 to 1.64)
 Levonorgestrel 6972 1 1.16 (0.16 to 8.23)
 Desogestrel 12 155 0 —
Current or recent use of progestogen-only contraception—non-oral 
 MPA depot 7321 3 6.56 (2.11 to 20.40)
 Implant 10 575 0 —
 LNG-IUS 172 265 18 0.84 (0.53 to 1.35)
LNG-IUS=levonorgestrel intrauterine system; MPA=medroxyprogesterone acetate.
*Adjusted for calendar year, parity, age, education, tubal sterilisation, hysterectomy, endometriosis, polycystic ovary syndrome, and family history of breast 
or ovarian cancer.
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evidence of important differences was seen between 
the combined oral contraceptives. Furthermore, when 
we restricted our analysis to women with complete 
contraceptive histories (in whom misclassification from 
unknown previous use could not occur), the pattern of 
results for individual combinations was similar, albeit 
with imprecise, non-significant risk estimates.
comparison with other studies
By contrast with most previous research, our study 
included women aged 15-49 years, most of whom 
will have been premenopausal. Thus, the periods of 
observation for ever users of hormonal contraceptives 
in this age group had a higher proportion of information 
relating to current or recent use than those for ever 
users in a study recruiting older women, because many 
would have stopped using hormonal contraception 
many years previously. The Collaborative Group on 
Epidemiological Studies of Ovarian Cancer’s reanalysis 
of oral contraception data from 45 studies included 
women who were generally older than our cohort (mean 
age of diagnosis of ovarian cancer was 56 years, with 
only 18% of tumours diagnosed in women younger 
than 45 years).4 The overall relative risk between ever 
and never users was 0.73 (95% confidence interval 
0.70 to 0.76). The Collaborative Group’s analysis 
found that younger and premenopausal women 
seemed to have greater percentage reductions in risk 
of ovarian cancer per five years of oral contraceptive 
use.4 However, after accounting for time since last use, 
no significant heterogeneity by menopausal status or 
age was seen, demonstrating that how recent a woman 
last used hormonal contraceptives was more important 
than the other two factors. Our slightly stronger 
reduced risk for any ovarian cancer among ever users 
of any hormonal contraception (relative risk 0.66 (95% 
confidence interval 0.58 to 0.76)) was possibly due to 
58% of the total period of observation in ever users 
arising from current or recent use of combined oral 
contraceptives.
Similar to the Collaborative Group4 and other 
more recent investigations,5-9 we found that the risk 
reductions among current users of any hormonal 
contraception got stronger with longer durations of use 
and persisted for a number of years after stopping use. 
The apparent loss of protection 10 years after stopping 
hormonal contraception could be due to the loss of 
biological effect (assuming a causal association exists), 
or reduced statistical power to continue to observe a 
significant reduction due to the relatively small periods 
of observation (7% of total person years for ever use).
Studies4 5 have not found differences in ovarian 
cancer risk by oestrogen dose of combined oral 
contraceptives (when assessed by decade of use). The 
same studies were unable to investigate associations 
with combined pills containing different progestogens. 
table 5 | relative risk of different histological types of ovarian cancer associated with hormonal contraception (full 
cohort), by categories of hormonal contraception use
Histology and use category no of person years no of cancer events adjusted relative risk (95% ci)*
epithelial ovarian cancer
Any epithelial ovarian cancer — 902 —
 Never use 8 150 250 566 1.00
 Current or recent use 8 839 374 155 0.58 (0.47 to 0.70)
 Former use 4 505 157 181 0.75 (0.62 to 0.91)
Clear cell epithelial ovarian cancer — 61 — 
 Never use 8 150 250 41 1.00
 Current or recent use 8 839 374 9 0.59 (0.28 to 1.27)
 Former use 4 505 157 11 0.68 (0.32 to 1.41)
Endometrioid epithelial ovarian cancer — 135 — 
 Never use 8 150 250 93 1.00
 Current or recent use 8 839 374 21 0.58 (0.35 to 0.96)
 Former use 4 505 157 21 0.64 (0.38 to 1.06)
Mucinous epithelial ovarian cancer — 204 —
 Never use 8 150 250 107 1.00
 Current or recent use 8 839 374 45 0.65 (0.44 to 0.97)
 Former use 4 505 157 52 0.96 (0.65 to 1.41)
Serous epithelial ovarian cancer — 502 — 
 Never use 8 150 250 325 1.00
 Current or recent use 8 839 374 80 0.55 (0.42 to 0.72)
 Former use 4 505 157 97 0.72 (0.56 to 0.93)
non-epithelial ovarian cancer
No of ovarian cancer events — 73 —
Never use 8 150 250 33 1.00
Current or recent use 8 839 374 21 0.64 (0.34 to 1.20)
Former use 4 505 157 19 1.09 (0.57 to 2.08)
Malignant tumour not otherwise specified
No of ovarian cancer events — 274 — 
Never use 8 150 250 172 1.00
Current or recent use 8 839 374 58 0.57 (0.41 to 0.80)
Former use 4 505 157 44 0.73 (0.50 to 1.05)
*Adjusted for calendar year, parity, age, education, tubal sterilisation, hysterectomy, endometriosis, polycystic ovary syndrome, and family history of breast 
or ovarian cancer.
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The Nurses’ Health Study II reported that short term use 
of preparations containing the oestrogen mestranol 
(hazard ratio 1.83, 95% confidence interval 1.16 to 
2.88) and first generation progestogens (1.72, 1.11 to 
2.65) were associated with an increased ovarian cancer 
risk, but found no relation with those containing 
second generation progestogens (levonorgestrel and 
norgestrel).22 The Nurses’ study had insufficient data 
to provide risk estimates for products containing 
desogestrel, norgestimate, or drospirenone. 
Although we lacked power to examine patterns of risk 
by duration of use and progestogen type, we had good 
statistical power for the most often used progestogens 
and found little evidence of important differences in 
overall ovarian cancer risk among current or recent 
users of combined preparations containing different 
progestogens. It has been suggested that combined oral 
contraceptives do not differ from progestogen-only pills 
in their risk of ovarian cancer.27 In our study, current 
or recent use of progestogen-only products among all 
women implied a smaller effect on ovarian cancer risk 
estimates, compared with users of combined products 
(table 2). In the no change cohort followed up to the 
first switch in hormonal contraception, no protection 
against ovarian cancer was seen in users of progestogen-
only products (table 4). This risk estimate was based on 
only 26 events, and so had limited statistical power to 
detect a significant protective effect. Alternatively, the 
lack of significance could be because of an absence 
of biological effect from progestogen-only products, 
with the reduced risk estimates seen in the full cohort 
analysis due to lingering effects from previous combined 
pill usage, suggesting that the protection found in the 
full cohort analysis could be due to a lingering effect 
from previous combined pill usage.
Few studies have examined use of depot 
medroxyprogesterone,14-16 with findings from those 
studies able to investigate exclusive use14 16 suggesting 
a protective effect. Our finding of an increased risk was 
based on only three exposed ovarian cancers and a 
very small total observation period, resulting in very 
imprecise risk estimates.
Soini and colleagues12 13 reported a standardised 
incidence ratio of 0.60 (95% confidence interval 0.45 
to 0.76) for ovarian cancer and use of the levonorgestrel 
intrauterine system among women in Finland,12 
with decreased risks for mucinous, endometrioid, 
and serous ovarian carcinomas.13 Our findings do 
not concur with those studies, possibly because the 
Finnish studies did not adjust for parity or previous 
use of oral contraceptives (shown to have a persisting 
protective effect).
The Ovarian Cancer Cohort Consortium (OC3) 
recently examined risk factors for different histological 
types of ovarian cancer among more than 1.2 million 
women from 21 prospective studies in Europe, Asia, 
and North America. The consortium found that a five 
year increase in duration of oral contraceptive use and 
more than 10 years of use were both associated with 
a decreased risk of serous, endometrioid, and clear 
cell tumours but not mucinous tumours.28 Similarly, 
the Collaborative Group on Epidemiological Studies 
of Ovarian Cancer found that oral contraceptive use 
was not associated with the incidence of mucinous 
tumours.4 It is important to note that our study 
investigated women of reproductive age and who were 
younger than those in both the OC3 (median age at 
diagnosis 61.3-68.9 years depending on histological 
tumour type) and Collaborative Group (mean age at 
diagnosis 56 years) studies. 
Our findings suggest that the protective effects of 
current or recent use of hormonal contraception is 
similar among endometrioid, mucinous and serous 
types of epithelial ovarian cancer. In line with current 
understanding, most mucinous tumours in our study 
were diagnosed at FIGO stage I.29 However, only 3% 
of all ovarian cancers are now thought to be mucinous 
types,29 indicating a relatively high incidence of 
mucinous tumours in our cohort. This high incidence 
of mucinous tumours has been observed previously in 
Denmark30 and elsewhere,28 and it is widely recognised 
that improvements in pathology, imaging, and serum 
markers will alter the reporting of the morphological 
subtypes of ovarian cancer.29 Therefore, some of the 
epithelial tumours could have been misclassified 
as mucinous.30 Recent understanding suggests that 
although ovarian cancer is clinically considered 
to be one disease, it is in fact a heterogeneous 
group of neoplasms with different pathogenesis 
pathways.29 Combined hormonal contraceptives 
suppress ovulation so protection against neoplastic 
development is feasible, but the exact mechanisms by 
which hormonal contraceptives reduce ovarian cancer 
risk are unclear. Whatever the biological mechanisms, 
the epidemiological evidence suggests a longlasting 
protection against most types of ovarian cancer from 
combined oral contraception.4 28
It has been suggested that recent downward trends 
in ovarian cancer mortality rates in North America and 
Europe can be partly attributed to the use of combined 
oral contraceptives.31 We found a population prevented 
fraction of 21% with use of hormonal contraception, 
which supports the notion that these ovarian cancer 
mortality benefits are likely to continue.
conclusions
Based on results from our prospective study, 
contemporary combined hormonal contraceptives are 
still associated with a reduced risk of ovarian cancer 
in women of reproductive age, with patterns similar 
to those seen with older combined oral products. 
The reduced risk seems to persist after stopping use, 
although it is not yet known how long for. Presently, 
there is insufficient evidence to suggest similar 
protection among exclusive users of progestogen-only 
products.
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